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Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or
APE1) is a multifunctional protein that regulates numerous transcription
factors associated with cancer-related pathways. Because APE1 is essential
for cell viability, generation of APE1-knockout cell lines and determining a
comprehensive list of genes regulated by APE1 has not been possible. To
circumvent this challenge, we utilized single-cell RNA sequencing to iden-
tify differentially expressed genes (DEGs) in relation to APE1 protein
levels within the cell. Using a straightforward yet novel statistical design,
we identified 2837 genes whose expression is significantly changed following
APE1 knockdown. Using this gene expression profile, we identified multi-
ple new pathways not previously linked to APE1, including the EIF2 sig-
naling and mechanistic target of Rapamycin pathways and a number of
mitochondrial-related pathways. We demonstrate that APE1 has an effect
on modifying gene expression up to a threshold of APE1 expression,
demonstrating that it is not necessary to completely knockout APE1 in
cells to accurately study APE1 function. We validated the findings using a
selection of the DEGs along with siRNA knockdown and qRT-PCR. Test-
ing additional patient-derived pancreatic cancer cells reveals particular
genes (ITGA1, TNFAIP2, COMMD7, RAB3D) that respond to APE1
knockdown similarly across all the cell lines. Furthermore, we verified that
the redox function of APE1 was responsible for driving gene expression of
mitochondrial genes such as PRDX5 and genes that are important for pro-
liferation such as SIPA1 and RAB3D by treating with APE1 redox-specific
inhibitor, APX3330. Our study identifies several novel genes and pathways
affected by APE1, as well as tumor subtype specificity. These findings will
allow for hypothesis-driven approaches to generate combination therapies
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using, for example, APE1 inhibitor APX3330 with other approved FDA
drugs in an innovative manner for pancreatic and other cancer treatments.
1. Introduction
Apurinic/apyrimidinic endonuclease 1/redox factor-1
(APE1/Ref-1; henceforth referred to as APE1) is a
multifunctional protein that is involved in repairing
DNA damage via its endonuclease activity in base
excision repair (Fung and Demple, 2005; Izumi et al.,
2005; Jiang et al., 2009; Kelley et al., 2014), and using
its redox protein–protein signaling function to control
the activity of numerous transcription factors such as
STAT3, NFjB, AP-1, p53, and hypoxia-inducible fac-
tor 1a (HIF1a), among others (Cardoso et al., 2012;
Fishel et al., 2015; Gaiddon et al., 1999; Jiang et al.,
2010; Kelley et al., 2012; Lando et al., 2000; Logsdon
et al., 2016). It also contributes to the removal of
damaged bases within RNA (Poletto et al., 2016;
Vascotto et al., 2014).
APE1 expression is increased in several cancers such
as pancreatic (Jiang et al., 2010), prostate (Kelley
et al., 2001), cervical (Xu et al., 1997), gliomas
(Bobola et al., 2004), lung (Yoo et al., 2008), bladder
(Shin et al., 2015), colon (Lou et al., 2014), and ovar-
ian cancers (Al-Attar et al., 2010; Zhang et al., 2009),
and this increase is associated with resistance to radia-
tion and chemotherapy, leading to poorer patient
prognosis (Sharbeen et al., 2015). Based on its involve-
ment in cancer, and its regulation of several transcrip-
tion factors associated with cancer-related pathways,
APE1 has become a prime target for anticancer thera-
pies (Fishel and Kelley, 2007; Kelley et al., 2014). Par-
ticular interest has been assigned to determining the
different genes and pathways affected by APE1.
While a number of studies have investigated genes
regulated by APE1, and specifically its redox signaling
function (Cardoso et al., 2012; Fishel et al., 2015; Gaid-
don et al., 1999; Jiang et al., 2010; Kelley et al., 2012;
Lando et al., 2000; Logsdon et al., 2016; Nishi et al.,
2002; Xanthoudakis et al., 1992), it has been difficult to
compile a comprehensive list of genes regulated by
APE1 as it is essential for cell viability. APE1-knockout
in mice results in embryonic lethality, postimplantation,
between days E5-E9 (Ludwig et al., 1998; Xan-
thoudakis et al., 1996). Subsequently, it is not possible
to generate stable APE1-knockout cell lines (Tell et al.,
2009). Approaches to circumvent this dilemma have uti-
lized conditional knockouts and siRNA knockdowns
(Fung and Demple, 2005; Izumi et al., 2005; Jiang
et al., 2010). For example, using siRNA knockdowns,
our laboratory has previously identified APE1 directly
regulating STAT3 transcriptional activity (Cardoso
et al., 2012), suppressing Nrf2-induced gene expression
(Fishel et al., 2015) and, most recently, regulating car-
bonic anhydrase 9 (CA9) via HIF-1a under hypoxic
conditions (Logsdon et al., 2016).
While APE1 knockdowns via siRNA are useful, this
approach produces a heterogeneous population, result-
ing in cells with differing amounts of the APE1 pro-
tein. Additionally, siRNA knockdowns are transient
with APE1 expression recovering over time (Jiang
et al., 2010). Consequently, there may be a limit to the
amount of information gained using APE1 siRNA in
a mixed population. In order to address this problem
and more accurately detect changes to the potential
numerous effectors regulated by APE1, we utilized
single-cell RNA sequencing (scRNA-seq).
In the studies presented here, APE1 was knocked
down using siRNA in low-passage patient-derived
pancreatic ductal adenocarcinoma (PDAC) cells, and
the resulting cells, together with control cells treated
with scrambled siRNA, were analyzed using scRNA-
seq. The data were analyzed by employing a straight-
forward yet novel statistical design that utilized the
BPSC R package (Vu et al., 2016) to accurately deter-
mine which genes were differentially expressed in
response to varying APE1 expression levels per cell.
Pathway analysis identified numerous pathways influ-
enced by APE1 knockdown, including eukaryotic ini-
tiation factor 2 (EIF2) signaling, protein kinase A
signaling, and mechanistic target of Rapamycin
(mTOR) signaling. Using data from The Cancer Gen-
ome Atlas (TCGA) (Cancer Genome Atlas Research
Network et al., 2013), the clinical relevance of the
differentially expressed genes (DEGs) was assessed by
fitting a Cox proportional hazards model. A number
of the DEGs were validated in a heterogeneous
APE1 population using siRNA knockdown and
quantitative real-time PCR (qRT-PCR). A subgroup
of genes analyzed demonstrated disparate expression
in response to APE1 reduction in additional patient-
derived PDAC cells. Four selected genes exhibited
dose-dependent decrease in expression in response to
treatment with APE1 redox inhibitor APX3330,
establishing the role of APE1 redox activity in regu-
lating their expression.
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This is the first report, to our knowledge, using sin-
gle-cell RNA-seq in a low-passage patient-derived
tumor cell with siRNA knockdown. Furthermore, this
technology provides us a way to understand the effects
of knocking down a protein, APE1 with transcrip-
tional regulation and DNA repair activities more com-
pletely as we can assess APE1 levels in each cell and
then correlate that with gene expression. Additionally,
the subsequent analyses determined unique pathways
altered when APE1 is knocked down, but not neces-
sarily depleted from the cells. Using an unbiased
approach to identify new, putative partners and path-
ways for APE1 in PDAC cells, we have identified
novel targets for further study of APE1-based combi-
nation therapies for PDAC treatment, as well as
potential for additional cancer indications.
2. Materials and methods
2.1. Cell culture
Pa03C, Pa02C, Panc10.05, and Panc198 (Pa20C) were
obtained from A. Maitra at The Johns Hopkins
University (Jones et al., 2008). All cells were main-
tained at 37 °C in 5% CO2 and grown in DMEM
(Invitrogen, Carlsbad, CA, USA) with 10% serum
(Hyclone, Logan, UT, USA). Cell line identity was
confirmed by DNA fingerprint analysis (IDEXX BioR-
esearch, Columbia, MO, USA) for species and baseline
short tandem repeat analysis testing in February 2017.
All cell lines were 100% human and a nine-marker
short tandem repeat analysis is on file. They were also
confirmed to be mycoplasma free.
2.2. Transfection with APE1 and scrambled
siRNA
The siRNA used were scrambled (SCR) (50 CCAUGA
GGUCAGCAUGGUCUG 30, 50 GACCAUGCUGAC
CUCAUGGAA 30) and siAPE1 (50 GUCUGGUACG
ACUGGAGUACC 30, 50 UACUCCAGUCGUACCAG
ACCU 30). All siRNA transfections were performed as
previously described (Fan et al., 2003; Fishel et al., 2008,
2010; Logsdon et al., 2016; Wang et al., 2004). Briefly,
1 9 105 cells are plated per well of a six-well plate and
allowed to attach overnight. The next day, Lipofectamine
RNAiMAX reagent (Invitrogen) was used to transfect in
the APE1 and SCR siRNA at concentrations between 10
and 50 nM following the manufacturer’s indicated proto-
col. Opti-MEM, siRNA, and Lipofectamine were left on
the cells for 16 h, and then, regular DMEM with 10%
serum were added. Cells were assayed for RNA and pro-
tein expression 3 days following transfection.
2.3. APX3330 treatment
APX3330 was prepared as previously described (Fishel
et al., 2010; Su et al., 2011). 2 9 105 Pa02C cells are
plated per well of a six-well plate and allowed to
attach overnight. The next day, APX3330 in low-
serum (2%) DMEM at 20 and 40 lM was added to
the wells. DMSO was used as the vehicle control. Cells
were treated for 24 h, after which they were collected
for RNA expression analysis.
2.4. Western blot analysis
For whole-cell lysates, cells were harvested, then lysed
in RIPA buffer (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and protein was quantified and elec-
trophoresed. Immunoblotting was performed using the
following antibodies: APE1 (Novus Biologicals, Little-
ton, CO, USA) and vinculin (Sigma, St. Louis, MO,
USA). For qRT-PCR experiments, APE1 expression
was at least 80% decreased compared to scrambled
control in order to be considered for further analysis.
2.5. Single-cell RNA sequencing
Three days post-transfection, SCR/siAPE1 cells were col-
lected and loaded into 96-well microfluidic C1 Fluidigm
array (Fluidigm, South San Francisco, CA, USA). All
chambers were visually assessed and any chamber con-
taining dead or multiple cells was excluded. The SMAR-
Ter system (Clontech, Mountain View, CA, USA) was
used to generate cDNA from captured single cells. The
double-stranded complimentary DNA quantity and
quality were assessed using an Agilent Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA, USA) with the High
Sensitivity DNA Chip. A total of 48 SCR and 48 siAPE1
cells were chosen for sequencing. The Purdue Genomics
Facility prepared libraries using a Nextera kit (Illumina,
San Diego, CA, USA). Unstranded 2 9 100 bp reads
were sequenced using the HiSeq2500 (Illumina, San
Diego, CA, USA) on rapid run mode in one lane. RNA-
seq data are available at the Gene Expression Omnibus
(GEO) through accession number GSE99305.
2.6. Bioinformatics and statistical analyses
Read quality was observed using FASTQC v. 0.11.2
(Andrews, 2010), and then, quality trimming was per-
formed using FASTX-Toolkit v. 0.0.13.2 (Gordon,
2009). A FASTX trimscore of 30 and a trim length of 50
were used. TOPHAT2 (Kim et al., 2013; Trapnell et al.,
2009) was used to align trimmed reads to the human
genome (ENSEMBL version GrCh38.p7). One
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mismatch was allowed. The htseq-count script in HTSEQ
v.0.6.1 (Anders et al., 2015) was run to count the num-
ber of reads mapping to each gene. HTSEQ used BIOPY-
THON v.2.7.3 in the analysis. In order to determine
which genes were differentially expressed, we used the
R package BPSC (Vu et al., 2016), which is specifically
designed to analyze single-cell RNA-seq data.
In order to facilitate comparison of the additional
experimental designs in this study, the explicit mathe-
matical expression of the linear component of our gen-
eralized model used for the baseline differential
expression analysis is given by the following:
lij ¼ b0j þ b1jI½siAPE1i
where lij is the expected value of the beta-Poisson count
distribution of the ith cell for the jth gene, b0 is the inter-
cept, and b1 is the gene expression in log(counts per mil-
lion). The expression I[siAPE1]i is an indicator variable
that takes the value of one when a cell belongs to the
siAPE1-knockdown group. We can then test for differen-
tial expression of the jth gene using the null (denoted as
H0) and alternative (denoted asH1) hypotheses as follows:
H0 : b1j ¼ 0
H1 : b1j 6¼ 0
Furthermore, scRNA-seq allowed us to separate the
siAPE1 cells as having either undetectable APE1 (de-
fined as a cell with zero expression of APE1) or detect-
able APE1 (defined as a cell with greater than zero
expression of APE1). The model for analyzing these
three categories is given by
lij ¼ b0j þ b1jI½siAPE1iI½APE1[ 0i
þ b2jI½siAPE1iI½APE1 ¼ 0i
where the expression I[siAPE1]i I[APE1 > 0]i takes
the value of one when the ith cell both belongs to the
siAPE1 group and has nonzero APE1 expression (de-
tectable siAPE1). The expression I[siAPE1]i I
[APE1 > 0]i takes the value of one when the ith cell
belongs to the siAPE1 group and has no detectable
expression of APE1 (undetectable siAPE1). A test for
differential expression of the jth gene was performed
using the null and alternative hypotheses
H0 : b1j ¼ 0; b2j ¼ 0
H1 : Atleast one of b1j 6¼ 0 orb2j 6¼ 0
This model has two parameters that can be tested
for joint significance, whereas the initial SCR/siAPE1
model only had one parameter to test. While it is pos-
sible to estimate the joint significance with a single test
of both parameters, we computed the parameter-
specific significance in order to gain insight into the
individual differences between undetectable siAPE1
and detectable siAPE1 groups with respect to the SCR
control. In practice, we tested each of these parameters
separately and reported their joint significance of the
resulting P-values using Fisher’s method (Fisher,
1925). For two P-values P1j, P2j corresponding to test
of b1j, b2j for the jth gene, the combined test statistic is
described as
F ¼ 2 logðP1jÞ  2 logðP2jÞv24
where F is distributed as a chi-squared random vari-
able with four degrees of freedom under the null
hypothesis. The combined P-value P* is therefore
computed as
P ¼ 1 Pv24ðF\FÞ
where Pv24 denotes the cumulative distribution func-
tion of a v24 random variable and F* is the empirical
test statistic computed similar to F above, only using
the computed P-values for each gene.
Ingenuity pathway analysis (IPA) was utilized in
performing network analyses (QIAGEN Redwood
City, www.qiagen.com/ingenuity). An upstream regula-
tor analysis, canonical pathway analysis, mechanistic
networks analysis, causal network analysis, and down-
stream effects analysis were performed using IPA
(results were deemed significant for P < 0.05). Algo-
rithms and details of each type of network analysis are
presented in Kramer et al. (2014).
2.7. Quantitative real-time PCR
Quantitative real-time PCR was used to measure the
mRNA expression levels of the various genes identified
from the scRNA-seq analysis. Following transfection,
total RNA was extracted from cells using the Qiagen
RNeasy Mini kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. First-
strand cDNA was obtained from RNA using random
hexamers and MultiScribe reverse transcriptase
(Applied Biosystems, Foster City, CA, USA). Quanti-
tative PCR was performed using SYBR Green Real
Time PCR master mix (Applied Biosystems) in a
CFX96 Real Time detection system (Bio-Rad, Her-
cules, CA, USA). The relative quantitative mRNA
level was determined using the comparative Ct method
using ribosomal protein L6 (RPL6) (Pa03C) or actin
(Panc10.05, Panc 198, Pa02C) as the reference gene.
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The primers used for qRT-PCR are detailed in
Table S1. Experiments were performed in at least trip-
licate for each sample. Statistical analysis performed
using the 2DDCT method and analysis of covariance
(ANCOVA) models, as previously published (Fishel
et al., 2015).
3. Results
3.1. scRNA-seq Analysis of APE1-knockdown
cells
The siRNA knockdown of APE1 does not result in
complete loss of the APE1 protein, as detected by
western blotting, with 10–20% APE1 protein expres-
sion observed in the siAPE1 samples compared to the
scrambled controls (SCR) as shown by representative
western blot shown in Fig. 1A. We used 20 nM siRNA
as levels greater than this result in off-target effects
and cell killing not related to APE1 functions. There-
fore, in order to clearly identify changes in gene
expression specifically related to the amount of APE1
protein within each individual cell, single-cell RNA-seq
was performed on cells following APE1 siRNA
knockdown.
3.2. Correcting for batch effects using cell cycle-
annotated genes
Due to sample preparation constraints, the siAPE1
and SCR cells were split across three batches, with one
batch containing siAPE1 and two batches containing
SCR cells (SCR1 and SCR2). Differences between cell
batches were corrected by applying the scLVM R pack-
age (Buettner et al., 2015). In conjunction with
scLVM, the Biomart R package (Durinck et al., 2009)
was used to obtain a list of cell cycle-annotated genes.
Specifically, the Gene Ontology (GO) term
GO:0007049 (Gene Ontology Consortium, 2015) was
used to identify 189 genes with the annotation name
of ‘cell cycle’. Of these 189 genes, only 102 coincided
with the genes remaining in our analysis due to the
removal of genes exhibiting low expression across all
cells (gene detection rate quality control filtering). We
then fit a latent variable model to account for cell
cycle confounding while also incorporating treatment
and control covariates into the model. Using the fitted
latent variable model, it is then possible to regress out
the cell cycle confounding and compute a corrected
dataset. A more detailed explanation can be found in
the supplementary material of Buettner et al. (2015).
As an illustration, the plot in Fig. 1B demonstrates
the two principal components before correcting for cell
cycle and shows that the most influential source of
variation (i.e., the x-axis representing 6.84% of the
total variation) in the data corresponds to the axis
along which SCR1 and SCR2 cells are separated. In
contrast, the second most influential source of varia-
tion (i.e., the y-axis representing 4.57% of the total
variation) corresponds to the axis along which siAPE1
and SCR cells are separated.
In the principal components plot following cell cycle
correction (Fig. 1C), the SCR1 and SCR2 cells show
greater similarity, which results in the largest source of
variation (i.e., the horizontal axis representing 4.88%
of the total variation) now corresponding to the axis
along which the siAPE1 and SCR cells are separated.
Using cell cycle correction, we have effectively
removed the variation attributed to cell cycle-
annotated genes without removing the variation attrib-
uted to the differences between siAPE1 treatment and
scrambled control. Thus, the largest source of varia-
tion between the cells is now attributed to APE1
knockdown.
3.3. Differential expression of genes in the
siAPE1-knockdown and SCR control cells
Initially, 48 SCR cells and 48 siAPE1 cells were cap-
tured for sequencing. Two SCR and siAPE1 cells each
were discarded prior to sequencing due to the presence
of multiple cells in the capture site. Cell detection rates
(percentage of genes detected in each cell) and gene
detection rates (percentage of cells with a given gene
expressed) were used for statistical quality control. A
threshold of 5% was used for both detection rates,
resulting in a dataset of 94 cells and 15 351 genes.
With the median number reads per cell of 0.95 million,
we normalized the total number of reads per cell to
one million. After the aforementioned cell cycle correc-
tion was performed, a further three outlier cells were
removed as they demonstrated signs of PCR bias with
extremely high expression counts for some genes. After
all quality control measures and the removal of out-
liers, the number of genes detected per cell averaged
7095.7 using the original (i.e., prior to correcting for
cell cycle confounding) gene expression counts. For
each gene, the average number of cells with nonzero
gene counts was 42.1 using the original gene expres-
sion counts.
The average APE1 expression in the remaining 46
cells in the SCR group was 101.6 reads per million. Of
the siAPE1 cells (n = 45), 25 cells had no detectable
APE1 expression with zero APE1 counts. The remain-
ing 20 cells showed diminished APE1 expression, with
an average of 37.7 reads per million. A violin plot
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showing the distribution of the cells in each of these
groups can be found in Fig. 2A.
While there are many available software packages
that are commonly used for differential expression
analysis, there are important differences between them
in terms of what assumptions are made about the dis-
tribution of the count data arising from RNA-seq
experiments. Two such R packages that use a general-
ized linear model in order to model non-normally dis-
tributed data are edgeR (Robinson et al., 2010) and
BPSC (Vu et al., 2016). The package edgeR models
the counts with an overdispersed (larger variance)
Poisson distribution (also known as the negative-
binomial distribution), which is perhaps not
Fig. 1. APE1 expression and batch effects in cells following siRNA knockdown. (A) Representative western blot and densitometry analysis
of Pa03C cells following APE1 knockdown using 20 nM siRNA. Vinculin is used as loading control. siAPE1 samples had 10% APE1 levels in
comparison with the SCR control sample. (B) Principal components analysis of uncorrected gene expression data. (C) Principal components
analysis of corrected gene expression data. Following corrections for batch effects using cell cycle-annotated genes, the SCR1 and SCR2
groups come together along the x-axis to form a single SCR group.
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appropriate for single-cell RNA-seq data due to the
fact that there are many more zero counts in these
data (a phenomenon referred to as zero inflation) com-
pared to bulk RNA-seq. Our experimental results
using edgeR resulted in a large number of DEGs, with
a potentially high false discovery rate (data not
shown). Alternatively, the R package BPSC models the
counts in a more flexible beta-Poisson distribution that
can appropriately account for the zero inflation in the
single-cell data with the use of additional parameters
in the model. Although there are other packages that
are specifically developed for single-cell differential
expression, the BPSC package is relatively fast and
performs well when compared to these other packages
(Vu et al., 2016). Therefore, the BPSC R package was
used in this study for the differential expression analy-
sis between SCR cells (n = 46) and siAPE1-knockdown
cells (n = 45).
However, it is worth emphasizing that our model is
more sophisticated than simple linear regression, as
the distributional assumptions made about the data
are fundamentally different. The equations used to
generate the baseline differential expression analysis
are found in Materials and methods. With this statisti-
cal design, the BPSC R package reported 1950 DEGs
between the siAPE1 and SCR cells using a false
discovery rate cutoff of 5%.
Of these DEGs, 71.7% had lower expression levels
in the siAPE1 cells. In comparison, 58.5% of all genes
sequenced had lower expression in the siAPE1 cells,
although many of these genes had very low expression
overall (Fig. 2B). Using Fisher’s exact test (Fisher,
1922) on the number of genes with statistically signifi-
cantly increased/decreased expression vs genes with
nonsignificant changes in expression, we obtain a
P-value of 1016, a highly significant result. This indi-
cates that the predominantly inhibitory effect of APE1
knockdown on the DEGs is greater than any global
Fig. 2. Results of scRNA-seq and comparison of analyses. (A)
Violin plot illustrating the differences in APE1 RNA expression
counts per million (CPM) reads in the SCR, detectable siAPE1, and
undetectable siAPE1 samples. The color bar indicates expression
levels of APE1 in log2 CPM. (B) Mean expression and fold change
plot using SCR and siAPE1 cells as the two groups in the analysis.
Significantly DEGs in red exhibited upregulated expression, and
green genes had significantly downregulated expression. (C) Mean
expression and fold change plot using SCR, detectable siAPE1, and
undetectable siAPE1 cells in the analysis. Note that while the
analysis uses three separate groups, this plot uses SCR and
siAPE1 for calculation of the mean expression and fold change due
to the limitations of the graph.
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decrease in expression that may be caused due to
external factors (such as cell viability).
3.4. Identifying differentially expressed genes in
relation to APE1 levels within the cell
One of the advantages of performing scRNA-seq is
that it allows us to look at APE1 expression in each
individual cell. It is therefore possible to use this infor-
mation to categorize cells within the siAPE1 group as
having either undetectable APE1 (defined as a cell with
zero expression of APE1) or detectable APE1 (defined
as a cell with greater than zero expression of APE1).
As previously mentioned, within the siAPE1 group,
there were 25 cells with undetectable APE1 (hereafter
called undetectable siAPE1) and 20 cells exhibiting
detectable but reduced APE1 expression (hereafter
called detectable siAPE1).
The delineation of the siAPE1 cells allowed us to
consider the SCR control, detectable siAPE1, and
undetectable siAPE1 cells as three different categories.
Such a model is appropriate if we consider detectable
siAPE1 cells to be distinct from undetectable siAPE1
as well as SCR control cells.
This analysis allows us to detect differences that
may be present between SCR and detectable siAPE1
cells, between SCR and undetectable siAPE1 cells, or
between SCR and both categories of siAPE1 cells. We
found that this joint analysis guards against a single
outlier preventing a gene from being reported as differ-
entially expressed as one parameter may be reported
as insignificant but not the other. Additionally,
because the direction of the expression change in the
DEGs is expected to be consistent as we move from
the SCR group to the detectable siAPE1 group to
undetectable siAPE1 group, this experimental design
aids in the interpretation of results and helps to iden-
tify genes potentially affected by outliers. This SCR/
detectable siAPE1/undetectable siAPE1 analysis identi-
fied 2837 genes using a false discovery rate of 5%. Of
the 1950 DEGs identified in the SCR/siAPE1 analysis,
1945 (99.7%) were found to be differentially expressed
in this subsequent analysis. Additionally, 72.1% of the
DEGs were downregulated (Fig. 2C), similar to the
71.7% downregulated in the SCR/siAPE1 analysis.
This consistency indicated that the increase in number
of DEGs identified was due to the more rigorous sta-
tistical model, making it the preferable analysis.
Analysis was also performed to investigate which
genes were differentially expressed between the detect-
able and undetectable siAPE1 cells. This analysis is
statistically underpowered due to the smaller sample
size of the two cell groups. It resulted in only 60
DEGs being identified, indicating that the detectable
and undetectable siAPE1 cells had similar gene expres-
sion patterns, especially when compared to the SCR
control cells. When comparing the DEGs to the SCR/
detectable siAPE1/undetectable siAPE1 results, 42
genes were found to overlap, while only six genes over-
lapped with the SCR/siAPE1 analysis (Fig. 3A). These
six genes (TMEM45A, TMEM126A, TMEM154,
COMMD7, ISYNA1, and TNFAIP2) were the only
genes overlapping between all three analyses. Violin
plots illustrating the expression of these genes in rela-
tion to APE1 expression per cell are shown in
Fig. 3B–G. The presence of these six genes in all three
analyses confirms that as APE1 levels decrease, the
expression levels of these six genes change further.
3.5. Determining the clinical relevance of the
differentially expressed genes
One overarching objective of our studies is to ascertain
potential combinations of APE1 inhibition with clini-
cally approved drugs that impinge on pathways
impacted by altered APE1 expression, initially in pan-
creatic cancer, but eventually in other cancers. Toward
this goal, the clinical relevance of the DEGs identified
by the different analyses was investigated using TCGA
(Cancer Genome Atlas Research Network et al.,
2013), which contains data such as tumor gene expres-
sion and clinical outcomes from patients with cancer.
Due to the small number of DEGs identified in the
detectable siAPE1/undetectable siAPE1 analysis, it was
excluded from this TCGA analysis. Both the SCR/
siAPE1 and SCR/detectable siAPE1/undetectable
siAPE1 analyses were utilized. Performing this TCGA
analysis allowed us to measure the clinical relevance of
the DEGs identified in this study, and also provided a
performance metric for the two analyses.
We used the RTCGA toolbox (Samur, 2014) to ana-
lyze the data from the TCGA. In this analysis, a gene
is defined as clinically relevant if its expression level at
the time of sequencing is statistically significantly
related to the number of days until death in patients
with pancreatic cancer. The statistical significance of a
gene is determined using the Cox proportional hazards
regression model (Cox, 1972), a commonly used model
in clinical trials and biostatistics. Specifically, we
regressed the outcome of days until death (accounting
for censoring due to a patient still being alive at the
time of sequencing) on the normalized gene expression
data of patient tumor samples via bulk RNA-seq using
the R package survival (Therneau, 2015). We chose to
include only expression levels in our analysis, modeling
one gene at a time across all tumor types and stages.
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Fig. 3. Identifying DEGs in relation to APE1 levels. (A) Venn diagram showing the three analyses performed on the scRNA-seq data and the
overlapping genes between them. Six genes were significantly changed in all three analyses, (B) TMEM45A, (C) TMEM126A, (D)
TMEM154, (E) COMMD7, (F) ISYNA1, and (G) TNFAIP2. These genes show increased changes in expression as APE1 levels are reduced
further from SCR to detectable (but reduced) siAPE1 to undetectable siAPE1.
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In all, we included 178 patient tumor samples and con-
sidered a total of 20 501 genes. Due to naming con-
ventions and quality control procedures, only 10 292
were in common between the total number of genes
sequenced in our scRNA-seq analysis and the TCGA
analysis of survival outcomes. Therefore, for this anal-
ysis, we limit our discussion to only these 10 292
genes. For this reason, the total number of DEGs
reported below for both our differential expression
analyses are fewer than reported in previous sections.
The TCGA analysis resulted in 1627 genes statisti-
cally significantly related to time until death using a
false discovery rate of 5%. Of the 1486 DEGs consid-
ered from our SCR/siAPE1 analysis, 246 genes
(16.6%) were found to be clinically relevant. The
SCR/detectable siAPE1/undetectable siAPE1 analysis
identified 345 clinically relevant genes (16.3%) of the
available 2115 DEGs. The full results are available
online in the Gene Expression Onmibus (GEO), acces-
sion number GSE99305.
The SCR/detectable siAPE1/undetectable siAPE1
analysis identified more DEGs that are clinically rele-
vant without a change in the overall percentage of
clinically relevant genes. This further illustrates that
the 856 genes unique to the analysis are not statistical
anomalies but authentic results identified due to a
more stringent statistical model. Because of this result,
all following analyses were carried out using the SCR/
detectable siAPE1/undetectable siAPE1 results.
3.6. Gene expression patterns in cancer-related
pathways
Ingenuity pathway analysis was used to determine
pathways regulated by APE1 based on the DEGs pre-
viously identified in the SCR/detectable siAPE1/unde-
tectable siAPE1 analysis. Full pathway analysis results
are in Table S2. A total of 104 canonical pathways
were identified as overrepresented using a one-tailed
Fisher’s exact test (Fisher, 1922). Data presented in
Fig. 4A demonstrate the 20 most statistically signifi-
cant overrepresented pathways, six of which were pre-
viously unlinked to APE1. The EIF2 signaling
pathway (P = 1.58 9 1018) with 70 DEGs was found
to be the pathway most affected by APE1 knockdown.
An overview of the pathway with the genes that were
affected is presented in Fig. 4B, with a heatmap high-
lighting the 70 DEGs, and their expression in each cell
is shown in Fig. 4C. Other previously unlinked path-
ways were the mTor pathway (P = 3.98 9 1012) with
55 DEGs and the regulation of eIF4 and p7056K sig-
naling pathways (P = 3.63 9 109) with 42 DEGs.
These pathways, along with the virus entry via endo-
cytic pathway, regulation of actin-based motility by
Rho and putrescine degradation pathways, are now
putatively linked to APE1 based on our scRNA-seq
data, expanding APE1’s already diverse role within the
cell. In total, 44 pathways previously unassociated with
APE1 were identified in this study. These results high-
light the importance of single-cell RNA-seq in deter-
mining clear gene expression and pathway interactions.
A number of the significant pathways affected by
APE1 knockdown confirm previous observations and
therefore provided validation for the results. For
example, the HIF1a signaling pathway, shown to be
regulated by APE1 (Lando et al., 2000), was found to
be significantly downregulated in the pathway analysis
(P = 0.006). Similarly, the mitochondrial dysfunction
(P = 8.12 9 106) and Huntington’s disease signaling
(P = 4.07 9 104) pathways are both in the top ten
significantly overrepresented pathways affected by
APE1 knockdown. The mitochondrial dysfunction
pathway has 37 DEGs, while there are 42 DEGs in
the Huntington’s disease signaling pathway. Mito-
chondrial dysfunction is believed to play a role in
Huntington’s disease pathology, and prior studies
have demonstrated that APE1 is important for the
maintenance of mitochondrial function (Li et al.,
2012; Siddiqui et al., 2012). APE1 is also known to
participate in mitochondrial DNA repair functions
(Ballista-Hernandez et al., 2017; Stuart et al., 2004;
Vascotto et al., 2009). While APE1 is known to influ-
ence these pathways, this study expands our under-
standing of APE1 within the cell by implicating the
genes in the pathways that are affected by APE1
knockdown.
Fig. 4. Overrepresented canonical pathways. (A) The 20 most significantly overrepresented pathways following IPA on the SCR/detectable
siAPE1/undetectable siAPE1 results are shown. The x-axis shows the number of genes that were differentially expressed in the
overrepresented pathways. The percentages next to the pathway labels on the y-axis show the percentage of genes in the pathway which
are differentially expressed between SCR and siAPE1 cells. (B) Changes in the EIF2 pathway. The EIF2 pathway was the pathway most
affected by APE1 knockdown with 70 DEGs. Genes that are upregulated in siAPE1 cells are shown in pink, whereas those that are
downregulated are shown in green. Genes or complexes that were identified as differentially expressed are outlined in pink. (C) Heatmap
showing changes in expression of DEGs per cell involved in the EIF2 pathway. Box showing colors corresponding to normalized changes in
expression shown, with green indicating downregulation and red signifying upregulated genes.
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3.7. Validating scRNA-seq results using qRT-PCR
The scRNA-seq results of the SCR/siAPE1 analysis
were validated by performing qRT-PCR in Pa03C cells
following siRNA knockdown. A panel of genes, from
distinct pathways and showing varying changes
following knockdown, was chosen (Fig. 5A). These
genes were present in both the SCR/siAPE1 and
Fig. 5. Validation of scRNA-Seq by qRT-PCR in Pa03C cells. (A) Genes chosen for qRT-PCR validation following SCR/siAPE1 validation. (B)
Genes statistically significant in all three analyses chosen for qRT-PCR validation. (C) Expression of selected genes assessed via qRT-PCR in
Pa03C cells. The cells were collected after siRNA knockdown and assessed for a reduction in APE1 protein levels of 80% or greater. Each
graph is the result of three independent experiments, showing average fold change in siAPE samples compared to SCR  SD. *P < 0.05
(ANCOVA model). (D) Validation analysis. Relation between log2 fold changes following scRNA-Seq (x-axis) and qRT-PCR (y-axis). R2 = 0.82.
Linear regression analysis of the slope provided P < 0.0001. The 12 genes used for validation are color-coded.
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SCR/detectable siAPE1/undetectable siAPE1 analyses.
Efficiency of siRNA knockdown was assessed using
western blots, with only samples exhibiting greater
than 80% reduction in APE1 expression compared to
the scrambled controls chosen.
In addition, validation of three genes that were dif-
ferentially expressed and statistically significant in all
analyses (SCR/siAPE1, detectable siAPE1/undetectable
siAPE1, and SCR/detectable siAPE1/undetectable
siAPE1) was performed. The presence of these genes
(Fig. 5B) within all three analyses indicates that their
expression changes more dramatically with greater
APE1 knockdown.
The genes that showed statistically significantly
increased or decreased expression in scRNA-seq exhi-
bit changes in the same direction following qRT-PCR
(Fig. 5C), with a decrease seen in the mRNA levels of
CIRBP, COMMD7, ISYNA1, ITGA1, NOTCH3,
PRDX5, RAB3D, SIPA1, TAPBP, and TNFAIP2. The
expression of breast cancer resistance protein (BCRP)
and PPIF was significantly increased following knock-
down. We plotted the fold changes from scRNA-seq
against qRT-PCR fold changes in Fig. 5D. With an
R2 value of 0.82 and P < 0.0001 (linear regression
analysis), we confirmed that the fold changes were
consistent and validated the single-cell scRNA-seq
studies.
3.8. Differences in gene expression of PDAC cell
lines in response to APE1 siRNA knockdown
We proceeded to look at the effect of APE1 siRNA
knockdowns in other PDAC low-passage patient-
derived cells. The effect of APE1 knockdown on these
genes varied between the different patient lines, as
shown in Fig. 6.
Panc10.05 cells, derived from a primary PDAC
tumor, exhibited similar results to Pa03C cells, with
eight of the 12 genes showing similar changes in
expression (Fig. 6A). COMMD7, ITGA1, RAB3D,
SIPA1, TAPBP, and TNFAIP2 show decreased
expression, while BCRP and PPIF show increased
expression. In contrast, CIRBP, ISYNA1, NOTCH3,
and PRDX5 show no change in expression in the
Panc10.05 cells.
Panc198 cells, also originating from a primary tumor,
produced the most varied results (Fig. 6B). COMMD7,
ITGA1, RAB3D, and TNFAIP2 all showed significantly
decreased expression, while no change in expression was
seen for BCRP, CIRBP, ISYNA1, NOTCH3, PRDX5,
PPIF, SIPA1, and TAPBP.
Pa02C, a cell line generated from liver metastasis of
a patient with PDAC, showed generally similar gene
expression patterns to the Pa03C cells, which were also
isolated from PDAC liver metastasis. In Pa02C cells,
BCRP, COMMD7, ISYNA1, ITGA1, PRDX5,
RAB3D, SIPA1, and TNFAIP2 all demonstrated a
decrease in expression, while NOTCH3 and PPIF were
significantly increased following knockdown (Fig. 6C).
Interestingly, while changes in expression of BCRP
and NOTCH3 were significant, they were in opposing
directions to the changes seen in Pa03C cells.
COMMD7, ITGA1, RAB3D, and TNFAIP2 were
significantly changed in all four cell lines (Fig. 6D).
PPIF and SIPA1 were differentially expressed in
Pa03C, Pa02C, and Panc10.05 cells. TAPBP was dif-
ferentially expressed in Pa03C and Panc10.05. PRDX5,
ISYNA1, BCRP, and NOTCH3 were common
between Pa03C and Pa02C (with BCRP and NOTCH3
changing in opposite directions between the cell lines),
while CIRBP was only differentially expressed in
Pa03Cs.
3.9. Role of APE1 redox activity in differential
gene expression
The multifunctional nature of APE1 means that the
differential expression observed may be either in
response to altered APE1 redox signaling or BER
activity. In order to isolate the impact of reduced
APE1 redox signaling, Pa02C cells were treated with
the specific APE1 redox signaling inhibitor APX3330.
ITGA1, PRDX5, SIPA1, and RAB3D were analyzed,
chosen for their importance in pathways identified in
the IPA as well as pathways previously linked to
APE1. All four genes tested demonstrated significant
dose-dependent decreases in gene expression when
treated with APX3330 compared to vehicle control
(Fig. 6E).
4. Discussion
In this study, we used single-cell RNA-seq to examine
the effects of APE1 knockdown in patient-derived
PDAC cells. Generating a significant amount of data,
we initially corrected for batch effects using cell cycle-
annotated genes. As detailed in Hicks et al. (2015),
scRNA-seq data often have batch effects that can
potentially confound the results of cell type identifica-
tion or, more applicable to this study, differential gene
expression. Without correction, such improper statisti-
cal design in testing the difference between the two
groups would lead to an increased number of false
positives in any further analyses.
Initial analyses looked for DEGs comparing the
SCR (n = 46) and siAPE1 (n = 45) cells regardless of
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APE1 expression level. This SCR/siAPE1 analysis
resulted in 1950 DEGs (Fig. 2B) and allowed us to
identify several new genes and pathways impacted by
APE1, including the EIF2 signaling and mTOR path-
ways and a significant number of mitochondrial-
related genes and pathways. However, employing
scRNA-seq meant that we could further analyze the
data without the limitations of bulk RNA studies. By
assessing the APE1 expression in each cell, we were
able to identify 25 cells in the siAPE1 group that
expressed no detectable APE1 (undetectable siAPE1),
while the remaining 20 cells expressed APE1 albeit at
Fig. 6. Different PDAC cell lines exhibit varied changes to expression of select genes following siRNA knockdown and APX3330 treatment.
Expression of selected genes assessed via qRT-PCR in (A) Panc10.05 cells (B) Panc198 cells and (C) Pa02C cells. The cells were collected
after siRNA knockdown and assessed for a reduction in APE1 protein levels of 80% or greater. Each graph is the result of at least three
independent experiments, showing average fold change in siAPE samples compared to SCR  SD. *P < 0.05 (ANCOVA model). (D) Venn
diagram showing the overlapping results of qRT-PCR between the four different PDAC cell lines. (E) Expression of genes assessed via qRT-
PCR following 24-hr APX3330 treatment in Pa02C cells. The graph is a result of three independent experiments, showing average fold
change in vehicle- and APX3330-treated samples compared to na€ıve control  SD. *P < 0.05, **P < 0.005, ***P < 0.001 (two-way ANOVA
applying Tukey’s post hoc multiple comparisons test).
14 Molecular Oncology (2017) ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Analyzing APE1 knockdown via single-cell RNA-seq F. Shah et al.
reduced levels compared to the SCR cells (detectable
siAPE1). Subsequently, this afforded us the opportu-
nity to perform a novel second analysis, in which we
identified DEGs between SCR cells and cells with
detectable APE1 as well as cells with undetectable
siAPE1, resulting in 2837 DEGs (Fig. 2C).
A third analysis was performed comparing the
detectable siAPE1 and undetectable siAPE1 cells. Only
60 genes were identified as differentially expressed
between these two groups, indicating their similar gene
expression patterns. Six of these genes overlapped with
the previous two analyses and were the only genes in
common between the three analyses (Fig. 3A). Thirty-
six DEGs overlapped between the SCR/detectable
siAPE1/undetectable siAPE1 and detectable siAPE1/
undetectable siAPE1 analyses. The appearance of 18
genes unique to the detectable siAPE1/undetectable
siAPE1 analysis is attributed to outliers and their out-
sized effect on the analysis due to the smaller sample
size of the analysis.
Only six genes overlapped between the three analy-
ses (TMEM45A, TMEM126A, TMEM154,
COMMD7, ISYNA1, and TNFAIP2) (Fig. 3A),
demonstrating that only these six genes were further
affected as APE1 levels decreased. This was an unex-
pected result, as we expected a larger number of genes
to change further as APE1 levels decrease. Conse-
quently, our results indicate that the change in expres-
sion of most genes following APE1 knockdown is
apparent when APE1 is at least reduced by 80%
(based on the number of APE1 transcripts in the
siAPE1 cells), and further reduction in APE1 does not
significantly increase or decrease most genes further.
In the case of several downregulated genes, this was
because initial APE1 knockdown (detectable siAPE1
cells) already reduced their expression to near zero,
which meant further reduction in APE1 (undetectable
siAPE1 cells) had no effect on them.
The Cancer Genome Atlas analysis helped us to pri-
oritize which analysis was preferable for follow-up
studies as the analysis comparing the SCR/detectable
siAPE1/undetectable siAPE1 analysis identified the
highest number of DEGs. We compared the results
from this analysis to two previous studies looking at
the effects of APE1 knockdown on gene expression in
a population of cells. The first study from Vascotto
et al. (2009) performed microarrays on RNA from
long-established HeLa cells with conditional APE1
siRNA knockdown. The gene list from this study con-
sisted of 858 unique gene names. Following removal of
genes due to different naming conventions and quality
control, 643 of those 858 genes overlapped with genes
considered in our analysis. The overlap between the
two studies resulted in 151 DEGs, with 85 genes
matching the direction of change in expression.
A second study from Illuzzi et al. (2017) used a
locus-specific targeting vector to generate haploinsuffi-
ciency in the established human colon cancer cell line,
HCT116. The heterozygous APE1-knockout cells
expressed approximately 50% APE1 level compared to
the parental line and were collected at passage five for
the microarray study. However, at the time of collec-
tion, the cells were near the end of their viability.
While this may influence the DEGs that were (and
were not) identified in the study, we compared the
results of our analysis to the 80 DEGs from this study.
Forty-four genes overlapped with the entire set of
genes (15 351) considered in our analysis, with 17
genes differentially expressed in both studies. Fourteen
of those were differentially expressed in the same
direction.
As demonstrated by our results presented here, gene
expression patterns in response to APE1 knockdown
vary between four different patient-derived PDAC cells
(Fig. 6D). Therefore, it is not a surprise to see only
17.6% overlap between our scRNA-seq results and
microarray data obtained from HeLa cells, and 17.5%
overlap with HCT116 cells when considering the total
number of DEGs identified in each respective study.
We assume some of these differences arise from differ-
ences in cancer subtypes as well as differences in APE1
expression between experimental conditions. A key
point when comparing these studies to our current
study is the consideration of the tumor cells utilized:
We used low-passage primary patient-derived tumor
cells, while the other studies were performed on long-
established laboratory-based tumor cell lines which
may have lost significant characteristics of human
tumors. Because scRNA-seq is a considerably more
sensitive and unbiased method of detection compared
to microarrays, the disparity in gene expression is most
likely amplified, making our current study more accu-
rate of the biology occurring in the cells.
The identification of the large number of DEGs in
our study allowed us to look at pathways most
affected by APE1 knockdown. IPA identified 104
pathways, with 60 previously linked and 44 unlinked
to APE1. One previously linked pathway of particular
interest is the mitochondrial dysfunction pathway.
APE1 redox and repair activity has previously been
shown to be responsible for maintaining and repairing
mitochondrial DNA (Ballista-Hernandez et al., 2017;
Li et al., 2012; Siddiqui et al., 2012; Stuart et al.,
2004; Vascotto et al., 2009). The results of our studies
presented here identify, for the first time, the genes
responsible for these functions. Among the 37 DEGs
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in the pathway are COX10 and PRDX5, both of which
are downregulated by APE1 knockdown. COX10 has
been shown to be essential for assembly and stability
of the mitochondrial electron transport chain com-
plexes I and IV (Diaz et al., 2006), and loss of PRDX5
sensitizes the cell to apoptosis by complex I inhibitors
(De Simoni et al., 2008; Kropotov et al., 2006). This
opens up the potential of combining APE1-based ther-
apies and existing mitochondrial complex inhibitors as
a novel approach to targeting cancer cells via inhibi-
tion of the mitochondrial dysfunction pathway. Fur-
ther analysis into the viability of the mitochondrial
dysfunction and other affected pathways identified in
this study as potential APE1-based combination ther-
apy targets is ongoing. Additionally, these results sup-
port the role of APE1 as a node in cancer signaling
(Shah et al., 2017).
For validation of the scRNA-seq, 12 novel genes
were chosen that have previously not been linked to
APE1. Nine of the genes are present in the SCR/
siAPE1 and SCR/detectable siAPE1/undetectable
siAPE1 analyses (Fig. 5A), while three were present in
all three analyses (Fig. 5B). Fold changes from the
SCR/siAPE1 analysis were used for comparative graph
and statistical analysis (Fig. 5D). While the SCR/de-
tectable siAPE1/undetectable siAPE1 analysis takes
maximal advantage of the scRNA-seq dataset, the
SCR/siAPE1 analysis comparing all SCR cells to
siAPE1 cells is an experimental design that can be
replicated in a laboratory setting where siRNA knock-
down results in a heterogeneous population.
The qRT-PCR results on the genes across the four
different patient-derived cell lines highlight the differ-
ences between individual patient tumors, as well as
between primary and metastatic tumors (Fig. 6D).
Pa03C and Pa02C, both liver metastases of patients
with PDAC (Embuscado et al., 2005), show similar
and statistically significant gene expression changes in
10 of 12 genes. However, BCRP and NOTCH3 exhib-
ited significant changes in opposite directions (Figs 5C
and 6C). In the primary PDAC cell lines Panc10.05
and Panc198 (Cui et al., 2012), NOTCH3 mRNA
levels are unchanged following APE1 knockdown,
while BCRP levels are significantly increased in
Panc10.05 (Fig. 6A,B). Both primary cell lines exhib-
ited mRNA expression patterns that were more similar
to each other than either metastatic line, although this
is a small subset of patient lines. The differing changes
in expression of BCRP and NOTCH3 emphasize the
importance of tumor profiling and precision oncology
in therapeutic strategies for PDAC, and the need to
target nodal proteins like APE1 that can affect
multiple pathways.
Breast cancer resistance protein/ABCG2 is an ATP-
binding cassette (ABC) transporter that is one of the
proteins responsible for multidrug resistance of cancer
cells (Mo and Zhang, 2012). In PDAC, high BCRP
expression corresponds to carcinogenesis, tumor pro-
gression, early recurrence, and poor survival (Lee
et al., 2012; Yuan et al., 2015). Several chemothera-
peutic drugs are substrates for BCRP, which results in
their efflux from and reduced accumulation within the
cells (Mo and Zhang, 2012). An affected drug of par-
ticular interest is 5-fluorouracil (Yuan et al., 2009),
which is currently part of the treatment regimen for
patients with PDAC (Ellenrieder et al., 2016). There-
fore, the discovery that APE1 knockdown affects
BCRP expression is crucial when looking at future
drug combinations to improve survival in PDAC.
Combining APE1-targeted agents with 5-FU in tumors
genetically similar to Pa02C should respond favorably
to this combination due to reduced BCRP expression.
A study in colon cancer stem cells indeed demon-
strated dramatically increased cell killing when 5-FU
and an inhibitor of APE1, APX3330, were used in vivo
(Lou et al., 2014).
NOTCH3, a highly conserved member of the epony-
mous Notch signaling pathway, has been implicated in
cell survival, proliferation, differentiation, develop-
ment, and homeostasis (Xiao et al., 2016). Increased
Notch3 protein levels have been identified as a prog-
nostic marker for patients with PDAC (Mann et al.,
2012), and lead to increased tumor invasion, metasta-
sis, and shortened patient survival (Zhou et al., 2016).
Because of this, Notch3 has become a target for novel
cancer therapies. c-secretase inhibitors and DLL4-
inhibiting antibodies both target proteins upstream of
Notch3, leading to the inhibition of the Notch signal-
ing pathway (Xiao et al., 2016). The identification of
Notch3 as being affected by APE1 opens up the possi-
bility of combining APE1-targeted therapies with these
inhibitors to enhance (in Pa03C) or counteract (in
Pa02C) the effects of APE1 inhibition on NOTCH3
expression and function in PDAC.
Of the 10 other genes validated, four of them,
COMMD7, ITGA1, RAB3D, and TNFAIP2, showed
decreased expression in all four patient cell lines
(Fig. 6D). COMMD7 (You et al., 2017), ITGA1
(Boudjadi et al., 2013; Gulubova, 2004; Schadendorf
et al., 1996), RAB3D (Luo et al., 2016; Yang et al.,
2015), and TNFAIP2 (Chen et al., 2011; Jia et al.,
2016) have all been shown to be upregulated in various
cancers including PDAC. While we cannot assume
these changes will be universal in all PDAC samples,
this consistency suggests that some of these genes
could make promising targets or biomarkers for
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APE1-based therapy or combination therapies that
potentially will be useful across multiple PDAC tumor
subtypes and in other tumor types.
In order to begin to correlate some of the key path-
ways that were elucidated with the IPA with the major
functions of APE1, we chose four genes to interrogate
following treatment with APE1 redox inhibitor
APX3330. This small-molecule inhibitor does not
affect APE1’s DNA repair function (Luo et al., 2008),
thereby allowing us to determine the result of blockade
of the redox activity of APE1 while not affecting
DNA repair, unlike the siRNA studies. Using APE1
redox-specific inhibitor APX3330, we tested four genes
that showed reduced expression in siAPE1 cells to
examine whether this downregulation was due to
impaired APE1 redox activity. These genes were cho-
sen based on their functions in highly significant path-
ways from IPA, as well as pathways previously
associated with APE1.
ITGA1, part of the integrin signaling and virus
entry via endocytic pathways as identified by IPA, is
involved in cell proliferation (Macias-Perez et al.,
2008) and invasion (Yang et al., 2003), as well as
inflammation (Becker et al., 2013) and fibrosis (Ramos
et al., 2012), which have all been previously linked to
APE1 (Aamann et al., 2016; Shah et al., 2017).
PRDX5 is part of the mitochondrial dysfunction
pathway as identified by IPA and plays a major in
protecting the cell from oxidative stress (De Simoni
et al., 2013). SIPA1 (Takahara et al., 2017; Zhang
et al., 2015) and RAB3D (Yang et al., 2015; Zhang
et al., 2017) are both involved in proliferation, inva-
sion, and metastasis in multiple cancers, exhibiting
similar functions to APE1. All four genes showing sig-
nificantly reduced expression in a dose-dependent man-
ner (Fig. 6E), establishing these genes are regulated by
APE1 redox activity.
However, these genes represent a fraction of the
genes identified in this initial study affected by APE1
knockdown. The identification of pathways formerly
unassociated with APE1, as well as known pathways
exhibiting DEGs not previously linked with APE1,
opens up novel targets for APE1-based combination
therapies. In fact, initial experiments targeting some of
the identified pathways in combination with APE1
inhibition appear to be promising and are the basis for
future studies.
5. Conclusions
This study takes an unbiased statistical approach to
determine the effects of APE1 knockdown in PDAC
cells. While it has been long known that APE1
regulates various essential transcription factors
(Cardoso et al., 2012; Fishel et al., 2015; Gaiddon
et al., 1999; Jiang et al., 2010; Kelley et al., 2012;
Lando et al., 2000; Logsdon et al., 2016), the amplified
effect of APE1 knockdown on downstream targets of
those transcription factors has not been previously elu-
cidated. Employing scRNA-seq for this investigation
allowed us to apply more stringent analytical models
to identify 2837 DEGs in Pa03C pancreatic cancer
cells. Based on this, we identified several new pathways
not previously known to be modulated by APE1
levels. We also demonstrate that APE1 appears to
have an effect on modifying gene expression to a
threshold of around 20% APE1. Reducing APE1
levels further does not significantly impact the target
genes. This demonstrates that it is not necessary to
completely knockout APE1 expression in cells to accu-
rately study APE1.
Solid tumor microenvironments, particularly PDAC,
are hypoxic, which leads to stabilization of HIF1a, a
transcription factor that regulates a multitude of pro-
teins involved in cell survival, proliferation, and inva-
sion (Masoud and Li, 2015). HIF1a transcriptional
activity is also regulated by APE1 (Fishel et al., 2011).
Similarly, STAT3 has been shown to work with HIF1a
in order to activate downstream targets in various can-
cers (Gariboldi et al., 2010; Pawlus et al., 2014), and
we have previously shown that APE1 interacts with
both STAT3 and HIF1a under hypoxia (Logsdon
et al., 2016). Single-cell RNA-seq under conditions of
APE1 knockdown and hypoxia would aid in further
dissection of the role of APE1 in regulating genes and
pathways that affect PDAC survival and invasion. As
a future direction, we have begun the APE1-
knockdown/hypoxia studies and anticipate the layering
of those findings with these to further refine a combi-
nation pathway strategy to attack PDAC in a hypoth-
esis-driven approach.
One other caveat exists in the studies as presented
here. We determined alteration of gene expression fol-
lowing APE1 knockdown. APE1, as discussed, has at
least two major roles in tumor cells; redox signaling
and DNA repair. Therefore, at this point in time, we
acknowledge that the altered gene expression is most
likely not solely due to alteration of redox signaling as
some pathways may have been altered in response to
reduced APE1 BER activity. While this study identifies
four genes as being regulated by APE1 redox activity,
this will be further addressed in future studies using
the specific APE1 redox signaling inhibitor, APX3330,
as well as second-generation analogs. APX3330 is a
novel, oral anticancer agent that specifically and selec-
tively inhibits APE1 redox activity without affecting
17Molecular Oncology (2017) ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
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APE1 endonuclease DNA repair activity (Fishel et al.,
2010; Luo et al., 2008; Su et al., 2011). It is the first
drug to target APE1 in cancer and enters clinical trials
in 2017. This brings forward the possibility of combin-
ing APX3330 with FDA-approved drugs that target
genes affected by loss of APE1 redox activity based on
patient tumor profile. This will allow us to precisely
target patient tumor subtypes to achieve drug-synthetic
lethality (Brunen and Bernards, 2017) in PDAC and
other cancers in the future.
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